Changing the future of Parkinson's disease.
Neuron23 is a clinical-stage biotechnology company combining human genetics and data science to develop precision medicines for Parkinson's disease. Its lead program targets LRRK2, a genetic driver of Parkinson's, using machine learning and functional genomics to identify and match patients to therapies. The company was founded in 2018 by a team of drug hunters, geneticists, and neuroscientists.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2025
Mar 2022
Dec 2020
Dec 2020
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
